New Case Report Published on Lanreotide Use in NET Patient Pregnancy

A new publication dated September 10, 2026 discusses lanreotide use in a patient case. The article, titled "Pregnancy in a patient with metastatic functioning midgut neuroendocrine tumor receiving lanreotide after peptide receptor radionuclide therapy," appears in Archives of Endocrinology and Metabolism. The publication describes a case involving a patient with metastatic functioning midgut neuroendocrine tumor who was receiving lanreotide following peptide receptor radionuclide therapy, and who experienced a pregnancy during this treatment course. This is reported as a case publication rather than a clinical trial or recall event. No outcome data, efficacy findings, or safety conclusions beyond the case description itself are included in the available event information. Lanreotide remains an approved compound, and this publication adds to the body of case-based literature involving its use in neuroendocrine tumor management. Readers interested in the clinical context of this case are encouraged to review the full article through the source link provided. For general background on lanreotide, its approved uses, and related publications, readers can consult the compound overview page.